SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 103 filers reported holding SYROS PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 2.35 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $145,000 | -48.6% | 121,809 | +223.3% | 0.00% | – |
| Q1 2021 | $282,000 | -88.9% | 37,680 | -83.9% | 0.00% | -100.0% |
| Q4 2020 | $2,536,000 | +50.1% | 233,687 | +22.2% | 0.00% | 0.0% |
| Q3 2020 | $1,690,000 | -31.8% | 191,177 | -17.7% | 0.00% | -33.3% |
| Q2 2020 | $2,477,000 | +392.4% | 232,429 | +174.0% | 0.00% | +200.0% |
| Q1 2020 | $503,000 | -50.5% | 84,818 | -42.3% | 0.00% | 0.0% |
| Q4 2019 | $1,017,000 | +34.3% | 147,077 | +101.6% | 0.00% | 0.0% |
| Q3 2019 | $757,000 | -13.3% | 72,938 | -22.7% | 0.00% | 0.0% |
| Q2 2019 | $873,000 | -15.2% | 94,326 | -16.3% | 0.00% | 0.0% |
| Q1 2019 | $1,030,000 | +107.7% | 112,690 | +26.8% | 0.00% | 0.0% |
| Q4 2018 | $496,000 | +303.3% | 88,882 | +763.7% | 0.00% | – |
| Q3 2018 | $123,000 | – | 10,291 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 3,139,895 | $23,486,000 | 4.50% |
| Samsara BioCapital, LLC | 2,189,199 | $14,769,000 | 2.72% |
| Bain Capital Life Sciences Investors, LLC | 5,785,036 | $43,272,000 | 2.45% |
| Omega Fund Management, LLC | 1,562,500 | $11,688,000 | 1.11% |
| Flagship Pioneering Inc. | 2,938,494 | $21,980,000 | 0.35% |
| EcoR1 Capital, LLC | 1,000,000 | $7,480,000 | 0.33% |
| Altium Capital Management LP | 126,702 | $948,000 | 0.26% |
| Nikko Asset Management Americas, Inc. | 5,042,009 | $37,714,000 | 0.18% |
| Artal Group S.A. | 1,025,000 | $7,667,000 | 0.14% |
| Orbimed Advisors | 1,837,500 | $13,745,000 | 0.13% |